A three-center randomized controlled trial in China enrolled 320 adults with both atrial fibrillation (AFib) and clinic-defined hypertension who underwent catheter ablation between February 2023 and January 2025. The study team randomly assigned 161 patients to receive sacubitril/valsartan at a reported dose of 100 mg once daily. One hundred fifty-nine patients were assigned to valsartan 80 mg once daily. Investigators chose valsartan as an active comparator because all participants required antihypertensive treatment; a placebo comparator was not used. The study was presented as a late-breaking abstract at the American Heart Association Scientific Sessions 2026 and the findings are preliminary until published in a peer-reviewed manuscript.
At 12 months after ablation, the cohort treated with the sacubitril/valsartan combination showed a lower rate of documented recurrence of AFib or related atrial tachyarrhythmias compared with the valsartan-alone cohort. The study team reported recurrence in 18% of participants in the sacubitril/valsartan arm versus 28.3% in the valsartan arm. Clinic systolic blood pressure fell by about 10 mm Hg in both groups during follow-up. Researchers also reported no meaningful difference in the reduction in 24-hour ambulatory blood pressure between the two treatment groups. Those parallel blood pressure reductions raise the possibility that mechanisms beyond simple blood pressure lowering contributed to the observed difference in arrhythmia recurrence.
Heart rhythm surveillance combined home-based handheld single-lead ECG recordings with in-clinic 12-lead ECGs and 24-hour Holter monitoring at scheduled visits. Visits were scheduled at 1, 3, 6 and 12 months for rhythm assessment. The monitoring approach was intermittent rather than continuous, so brief or asymptomatic AFib episodes could have been missed. The trial was open-label: treating clinicians and patients knew assigned treatments. Despite this, investigators arranged for central adjudication of ECG-documented recurrence events by an independent team blinded to treatment assignment. The abstract format presented at the meeting means the report has not undergone full peer review; the study team noted the results are preliminary pending full manuscript publication.
Participants averaged 68 years of age. Women comprised 41.2% of the cohort. Two-thirds (66.6%) had paroxysmal AFib. All participants had clinic blood pressure above 130/80 mm Hg at baseline and therefore required antihypertensive therapy after ablation. The trial ran at three hospitals in China and followed patients for 12 months post-ablation with scheduled monitoring visits and home ECG use. The study protocol, including selection criteria beyond age and hypertension threshold, detailed adverse-event reporting, and statistical analysis plans are described in the meeting abstract; the news release noted additional study information was provided by the researchers beyond the abstract text.
The authors listed several limitations. The open-label design permits potential performance or reporting bias, even though ECG recurrence events were adjudicated by a blinded committee. Intermittent rhythm monitoring may have missed short or asymptomatic AFib episodes, which could influence recurrence rates. The trial enrolled older adults with hypertension in China; applicability to younger patients, people without hypertension, or populations in other regions remains uncertain. The report did not present continuous-monitoring data, nor did it provide detailed information on adverse events or longer-term outcomes beyond 12 months in the news release.
Unanswered questions documented by the study team include whether the observed reduction in arrhythmia recurrence reflects a neprilysin-inhibition effect of sacubitril/valsartan beyond blood pressure control, and whether similar results would be observed with different dosing, in broader populations, or with longer follow-up. The investigators emphasized these findings are preliminary and await peer-reviewed publication for full evaluation. Funders reported support from multiple Chinese research agencies and institutional programs; investigators stated the funders did not influence study design, data collection, analysis, interpretation, manuscript preparation, or the decision to submit the results for publication.